The U.S. government is reportedly on the verge of reclassifying marijuana, a move that would reshape the financial landscape for the entire cannabis industry.
This potential shift of cannabis from a Schedule I to a Schedule III substance under the Controlled Substances Act is a momentous development. The journey to this point has been a long one, beginning with a directive from President Biden in 2022, followed by a scientific recommendation from the Department of Health and Human Services (HHS) in 2023. The process gained significant momentum when President Trump signed an executive order in late 2025 to accelerate the rulemaking, leading to the current expectation of a final decision.
So, what does this change actually mean for businesses? The most immediate and significant impact comes from relief from the IRS Code Section 280E. This tax rule currently prevents cannabis companies from deducting standard business expenses—like rent, payroll, or marketing—from their federal taxes because they are considered to be 'trafficking' a Schedule I substance. This has resulted in some companies facing effective tax rates of 70% or more, severely hindering their profitability and cash flow. Moving to Schedule III would eliminate this burden, potentially saving the industry hundreds of millions of dollars annually and allowing companies to operate on a more level playing field with other legal businesses.
However, it's crucial to understand the limits of this reclassification. First, it does not federally legalize cannabis for recreational adult use. That would require an act of Congress. Second, it does not automatically solve the industry's banking problems. Major financial institutions have been hesitant to serve cannabis businesses due to federal laws. While this move is a step in the right direction, broader access to banking and the ability for U.S. cannabis companies to list on major exchanges like the NYSE or Nasdaq likely still depend on further legislation, such as the SAFER Banking Act, and updated guidance from financial regulators.
In essence, while reclassification is not a silver bullet for all the industry's challenges, it represents a critical step toward financial normalization. It provides immediate, tangible relief that could boost investment and stability in a sector that has been eagerly awaiting federal reform.
- Glossary
- Schedule I Substance: A drug defined by the DEA as having no currently accepted medical use and a high potential for abuse. Examples include heroin and LSD.
- Schedule III Substance: A drug with a moderate to low potential for physical and psychological dependence and accepted medical use. Examples include ketamine and anabolic steroids.
- Section 280E: A section of the U.S. Internal Revenue Code that forbids businesses from deducting otherwise ordinary business expenses from gross income associated with the 'trafficking' of Schedule I or II substances.